Policy & Regulation
Caliway Biopharmaceuticals receives China trial clearance for CBL-514
20 November 2026 -

Taiwan-based clinical-stage drug developer Caliway Biopharmaceuticals (TWSE: 6919) said on Friday it has received authorisation from the Center for Drug Evaluation of China's National Medical Products Administration to proceed with CBL-0102, its China clinical trial for CBL-514, an injectable candidate for large-area localised fat reduction.

The clearance was granted earlier than anticipated, accelerating the programme's development timeline in China.

Subject enrolment is expected to begin in December 2026, with the study scheduled for completion in the second quarter of 2027 and clinical data anticipated shortly afterwards. Caliway Biopharmaceuticals said the results will support subsequent clinical development activities and regulatory submissions.

The randomised, open-label, single-dose study is expected to enrol around 30 healthy participants across two sites in China. It is designed to assess the effects of ethnic factors on the pharmacokinetic profile, safety and tolerability of CBL-514 in a Chinese population.

According to the company, data from Asian participants could support future Phase 3 studies and regulatory filings in China, while also informing submissions in other Asian markets.

Login
Username:

Password: